| CAS NO: | 1071-23-4 |
| 包装 | 价格(元) |
| 100mg | 电议 |
| 500mg | 电议 |
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 141.06 |
| Cas No. | 1071-23-4 |
| Formula | C2H8NO4P |
| Solubility | insoluble in EtOH; ≥3.53 mg/mL in DMSO with gentle warming and ultrasonic; ≥42.6 mg/mL in H2O |
| Chemical Name | 2-aminoethyl dihydrogen phosphate |
| Canonical SMILES | NCCOP(O)(O)=O |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
O-Phosphorylethanolamine, also known as O-phosphoethanolamine, is an endogenous phospholipid metabolite. O-Phosphorylethanolamine serves as a precursor in the biosynthesis of phosphatidylethanolamine which is the most abundant lipid on the cytoplasmic layer of cellular membranes, with significant roles in a variety of cellular processes such as membrane fusion, cell cycle, autophagy, and apoptosis. In postmortem brain samples from patients with Alzheimer's disease and Huntington's disease, it can be observed that levels of O-phosphorylethanolamine are significantly reduced, which is accompanied by increased neuronal death. In addition, lower levels of O-phosphorylethanolamine have also been found in the midbrain and the cerebrospinal fluid of patients with Parkinson’s disease.
References:
1. Pavlovic Z, Bakovic M. Regulation of Phosphatidylethanolamine Homeostasis—The Critical Role of CTP:Phosphoethanolamine Cytidylyltransferase (Pcyt2). International Journal of Molecular Sciences, 2013, 14(2): 2529-2550.
2. Ellison DW, Beal MF, Martin JB. Phosphoethanolamine and ethanolamine are decreased in Alzheimer's disease and Huntington's disease. Brain Research, 1987, 417(2): 389-392.
3. Patel D, Witt SN. Ethanolamine and Phosphatidylethanolamine: Partners in Health and Disease. Oxidative Medicine and Cellular Longevity, 2017, 2017: 4829180.
m.cnreagent.com